Creo Medical Group (LON:CREO) Shares Down 1.6% - Should You Sell?

Creo Medical Group PLC (LON:CREO - Get Free Report)'s share price dropped 1.6% on Monday . The company traded as low as GBX 13.75 ($0.19) and last traded at GBX 14.25 ($0.19). Approximately 429,776 shares were traded during mid-day trading, a decline of 69% from the average daily volume of 1,374,790 shares. The stock had previously closed at GBX 14.48 ($0.20).

Creo Medical Group Price Performance

The stock has a fifty day simple moving average of GBX 12.11 and a 200-day simple moving average of GBX 14.64. The company has a market capitalization of £57.61 million, a PE ratio of -2.26 and a beta of 0.86. The company has a current ratio of 3.24, a quick ratio of 2.19 and a debt-to-equity ratio of 29.96.

Creo Medical Group (LON:CREO - Get Free Report) last issued its earnings results on Monday, May 19th. The company reported GBX (8) (($0.11)) earnings per share for the quarter. Creo Medical Group had a negative return on equity of 41.79% and a negative net margin of 73.93%. Equities analysts anticipate that Creo Medical Group PLC will post -10.0800005 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Kevin Crofton bought 701,750 shares of Creo Medical Group stock in a transaction dated Friday, May 30th. The stock was acquired at an average cost of GBX 16 ($0.22) per share, with a total value of £112,280 ($152,017.33). 22.43% of the stock is owned by corporate insiders.

Creo Medical Group Company Profile

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy. The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.